DCVC Announcements
First Investment: 2014
EXIT - Acquisition (Ginkgo Bioworks: DNA)
Zymergen used machine learning and robotic labs to modify microbes to produce novel molecules and materials, including Hyaline, a flexible bio-based film for touch-sensitive displays. Ginkgo Bioworks acquired the company in 2022.
News & Insights
News
Biology-as-a-Platform in the Fight Against Cancer: Freenome Raises $270m Series C
News
Confluent IPO: Data In (Upward) Motion
News
Protecting the Digital World Around Us: SentinelOne IPO
News
From Seed to IPO: Zymergen Brings Biofacturing Public
Thoughts
An Update on How Deep Tech is Arming the Fight Against COVID-19
News
Pivot Bio Raises $100m Series C: Bringing Microbes to Millions...of Acres
Thoughts
Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech
Thoughts
Solving the world’s hardest problems with Deep Tech: Request for Startups
News
Zymergen, Series Seed and Series A led by DCVC, Raises $400M+ Series C: Revolutionizing global industry through molecular manufacturing
News
Zymergen, Mesosphere, Citrine & Desktop Metal named World Economic Forum Tech Pioneers
News
Data Collective Tops Up Previously Closed Fifth and Sixth Funds for a New Total of $387 Million
News
Bringing Zymergen to Scale: Enabling Engineering Biology with AI & Robotics
In The Media
Fierce Biotech
The top 10 medtech IPOs of 2021
Zymergen
Forbes
DCVC co Zymergen talks about using biology for industrial purposes at scale in Forbes
Zymergen
GenEngNews
GenEngNews talks to DCVC co Zymergen about how synthetic biology is tackling challenges in medicine, food, electronics and more
Zymergen
The Economist
The Economist features DCVC co Zymergen as it talks about how remaking life means automating biology
Zymergen
Associated Press
Zymergen Announces $400 Million in Series C Funding
Zymergen
Explore Companies
Newleos Therapeutics
Transforming the treatment of anxiety and other neuropsychiatric disorders
Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs